<DOC>
	<DOCNO>NCT02492334</DOCNO>
	<brief_summary>The study test efficacy doxazosin , long-acting selective alpha-1 adrenergic antagonist , compare placebo reduce PTSD symptomatology alcohol use severity .</brief_summary>
	<brief_title>Doxazosin PTSD Alcohol Use Disorder</brief_title>
	<detailed_description>As result sustain operation Afghanistan Iraq , increase number U.S. military personnel Veterans risk develop posttraumatic stress disorder ( PTSD ) alcohol use disorder ( AUD ) . If leave untreated , individual PTSD/AUD risk develop mental health problem ( e.g. , depression , anxiety ) , suicidal ideation attempt , physical health problem , reduce resiliency , vocational problem , family/relationship impairment . While mental health service place U.S. military personnel Veterans , substantial gap evidence base guide treatment co-occurring PTSD/AUD . The propose study directly address gap test efficacy doxazosin , long-acting selective alpha-1 adrenergic antagonist , compare placebo reduce PTSD symptomatology alcohol use severity among U.S. military personnel ( include National Guard Reservists ) serve Operation Enduring Freedom , Operation Iraqi Freedom , Operation New Dawn ( OEF/OIF/OND ) . The primary objective stage II study evaluate benefit doxazosin compare placebo reduce ( 1 ) PTSD symptomatology , ( 2 ) AUD severity , ( 3 ) impairment associate mental behavioral health problem ( e.g. , depression , anxiety , sleep , risky behavior ) among OEF/OIF/OND Veterans ( N=126 ) co-occurring PTSD AUD . Secondary objective characterize underlie pathophysiology comorbid PTSD/AUD identify prognostic indicator treatment outcome use functional magnetic resonance imaging ( fMRI ) . In order accomplish investigator ( 1 ) employ intent-to-treat , double-blind , placebo-controlled randomized clinical trial consist 12 week treatment doxazosin placebo medication ; ( 2 ) examine standardize , repeat dependent measure clinical outcome 5 time point ( baseline , week 4 , week 8 , week 12 , 1-month follow-up ) ; ( 3 ) employ advance neuroimaging methodology .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>1 . Male female ; race ethnicity ; age 21 65 year old . 2 . U.S. military veteran . 3 . Score &gt; 21 Mini Mental Status Exam . 4 . Subjects must able comprehend English . 5 . Meet DSM5 criterion current ( i.e. , last 6 month ) alcohol use disorder ( AUD ) . 6 . Meet DSM5 criterion current ( i.e. , last 6 month ) PTSD . 7 . Enrolled VAMC Substance Abuse Treatment Clinic ( SATC ) program . 8 . Subjects take psychotropic medication require maintain stable dose least eight week treatment initiation . 9 . Must consent random assignment doxazosin placebo . 10 . Must consent complete treatment followup visit . 11 . Must live within 50 mile Ralph H. Johnson VAMC Charleston , SC . 1 . DSM5 criteria history current psychotic bipolar affective disorder , current eat disorder , study protocol may therapeutically insufficient . 2 . DSM5 criteria another substance use disorder , except caffeine nicotine , within past 12 month . 3 . Subjects experience significant withdrawal symptom , evidence score 10 Clinical Institute Withdrawal Assessment Alcohol ( CIWA ) .These subject refer clinical detoxification may reassess study eligibility medically supervise detoxification complete . 4 . Individuals consider immediate suicide risk base Columbia Suicide Severity rating Scale ( CSSRS ) likely require hospitalization course study . 5 . Previous treatment doxazosin . 6 . Subjects maintenance anxiolytic , antidepressant , mood stabilize medication initiate past four week . If determine , base clinical criterion , subject need start maintenance medication anxiety , mood psychotic symptom course study , discontinue treatment trial . 7 . Women pregnant , nurse practice effective form birth control . 8 . Individuals history current medical illness include unstable angina , myocardial infarction , congestive heart failure cardiac condition , hypotension hypertension , renal hepatic disorder , endocrine disorder , prostate cancer , pancreatitis , seizure disorder . 9 . Subjects abnormal liver function test ( LFTs ) evidence laboratory finding SGOT SGPT great two time normal . 10 . Subjects history adverse reaction quinazolines alpha1antagonists ( allergic reaction , priapism , hepatitis , angioedema , intraoperative floppy iris syndrome ) . 11 . Individuals currently take medication treat hypertension , trazodone , hypnotics/benzodiazepines , mirtazapine , atypical antipsychotic , alpha2agonists , prazosin , conivaptan , boceprevir , fusidic acid , idelalisib , PDE5 inhibitor alpha1antagonists . 12 . MRI exclusion : Claustrophobia ; tattoos shoulder ; permanent eyeliner eyebrow ; cardiac pacemaker ; metal fragment eye , skin , body , include shrapnel ; heart valve replacement ; brain clip ; venous umbrella ; sheetmetal worker welder ; history aneurysm surgery ; intracranial bypass , renal , aortic clip ; prosthetic device middle ear , eye , joint , penile implant ; joint replacement ; nonremovable hearing aid , neurostimulator , insulin pump ; shunts/stents ; metal mesh/coil implant ; metal plate/pin/screws/wires ; metal implant .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>